Article
Oncology
Lola-Jade Palmieri, Tomas Buchler, Antoine Meyer, Veronika Veskrnova, Ondrej Fiala, Petr Brabec, Jana Baranova, Romain Coriat
Summary: This study compared patients receiving delayed anti-EGFR introduction, immediate anti-EGFR introduction, and immediate anti-VEGF introduction, finding no deleterious impact on survival from delaying anti-EGFR introduction compared to immediate anti-EGFR or anti-VEGF introduction.
Article
Biochemistry & Molecular Biology
Marion Thibaudin, Jean-David Fumet, Benoist Chibaudel, Jaafar Bennouna, Christophe Borg, Jerome Martin-Babau, Romain Cohen, Marianne Fonck, Julien Taieb, Emeric Limagne, Julie Blanc, Elise Ballot, Lea Hampe, Marjorie Bon, Susy Daumoine, Morgane Peroz, Hugo Mananet, Valentin Derangere, Romain Boidot, Henri-Alexandre Michaud, Caroline Laheurte, Olivier Adotevi, Aurelie Bertaut, Caroline Truntzer, Francois Ghiringhelli
Summary: Although chemotherapy with targeted therapies remains the only therapeutic option for microsatellite stable (MSS) tumors, a phase Ib/2 trial showed that the combination of durvalumab plus tremelimumab with mFOLFOX6 chemotherapy has promising clinical activity in RAS-mutant unresectable metastatic CRC patients, particularly in those with MSS tumors.
Article
Oncology
Lifeng Xiong, Yinmei Lou, Lin Wang
Summary: The combination of bevacizumab with chemotherapy can increase the overall response rate and disease control rate in patients with mCRC, significantly improve the resectability rate of metastases, prolong survival time and progression-free survival, and enhance quality of life.
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2021)
Article
Oncology
Toshikazu Moriwaki, Masahiko Gosho, Akinori Sugaya, Takeshi Yamada, Yoshiyuki Yamamoto, Ichinosuke Hyodo
Summary: The study suggests that a continuous induction therapy followed by FP/Bev alone, and switching to FP+Bev within approximately 4 months if induction therapy is discontinued, is the optimal maintenance therapy regimen for improving overall survival in patients with metastatic colorectal cancer.
CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Ran Jin, Adesuwa S. Ogbomo, Neil A. Accortt, Lincy S. Lal, Geetanjali Bishi, Darcie Sandschafer, Jerome H. Goldschmidt
Summary: This retrospective chart review study evaluated the effectiveness and tolerability of bevacizumab-awwb in the treatment of metastatic colorectal cancer patients. The results showed that the outcomes and tolerability of bevacizumab-awwb were comparable to Avastin reference product, consistent with previously published real-world studies.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Jun Watanabe, Kei Muro, Kohei Shitara, Kentaro Yamazaki, Manabu Shiozawa, Hisatsugu Ohori, Atsuo Takashima, Mitsuru Yokota, Akitaka Makiyama, Naoya Akazawa, Hitoshi Ojima, Yasuhiro Yuasa, Keisuke Miwa, Hirofumi Yasui, Eiji Oki, Takeo Sato, Takeshi Naitoh, Yoshito Komatsu, Takeshi Kato, Masamitsu Hihara, Junpei Soeda, Toshihiro Misumi, Kouji Yamamoto, Kiwamu Akagi, Atsushi Ochiai, Hiroyuki Uetake, Katsuya Tsuchihara, Takayuki Yoshino
Summary: Adding panitumumab to standard first-line chemotherapy significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer, particularly in those with left-sided tumors.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Oncology
Shun Yamamoto, Kengo Nagashima, Takeshi Kawakami, Seiichiro Mitani, Masato Komoda, Yasushi Tsuji, Naoki Izawa, Kentaro Kawakami, Yoshiyuki Yamamoto, Akitaka Makiyama, Kentaro Yamazaki, Toshiki Masuishi, Taito Esaki, Takako Eguchi Nakajima, Hiroyuki Okuda, Toshikazu Moriwaki, Narikazu Boku
Summary: This study found that in mCRC patients, those who experienced early progression in first-line chemotherapy showed poor clinical outcomes with second-line chemotherapy regardless of the use of anti-angiogenic agents.
Article
Oncology
I. Ray-Coquard, A. Leary, S. Pignata, C. Cropet, A. Gonzalez-Martin, C. Marth, S. Nagao, I. Vergote, N. Colombo, J. Maenpaa, F. Selle, J. Sehouli, D. Lorusso, E. M. Guerra Alia, G. Bogner, H. Yoshida, C. Lefeuvre-Plesse, P. Buderath, A. M. Mosconi, A. Lortholary, A. Burges, J. Medioni, A. El-Balat, M. Rodrigues, T. -W. Park-Simon, C. Dubot, D. Denschlag, B. You, E. Pujade-Lauraine, P. Harter
Summary: In the PAOLA-1/ENGOT-ov25 study, maintenance olaparib plus bevacizumab showed significant benefits in progression-free survival (PFS) for newly diagnosed advanced ovarian cancer patients, regardless of surgical status. The final analysis of overall survival (OS) confirmed the clinical benefit of olaparib plus bevacizumab, particularly in patients with HRD-positive ovarian cancer.
ANNALS OF ONCOLOGY
(2023)
Review
Oncology
Sara Cherri, Ester Oneda, Laura Zanotti, Alberto Zaniboni
Summary: Colorectal cancer is a significant health problem due to its incidence and biological complexity. Distinguishing different types of colorectal cancer based on specific characteristics is crucial for better therapeutic outcomes. The future challenge lies in studying effective combination treatments to overcome resistance mechanisms and achieve long-term treatment success. It is also important to prioritize the best therapies for first-line treatment and refine patient selection.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Marinde J. G. Bond, Karen Bolhuis, Olaf J. L. Loosveld, Jan Willem B. de Groot, Helga Droogendijk, Helgi H. Helgason, Mathijs P. Hendriks, Joost M. Klaase, Geert Kazemier, Mike S. L. Liem, Arjen M. Rijken, Cornelis Verhoef, Johannes H. W. de Wilt, Koert P. Jong, Michael F. Gerhards, Martinus J. van Amerongen, Marc R. W. Engelbrecht, Krijn P. van Lienden, I. Quintus Molenaar, Bart de Valk, Brigitte C. M. Haberkorn, Emile D. Kerver, Frans Erdkamp, Robbert J. van Alphen, Danielle Mathijssen-van Stein, Aysun Komurcu, Marta Lopez-Yurda, Rutger-Jan Swijnenburg, Cornelis J. A. Punt, Dutch Colorectal Canc Study Grp
Summary: This study compared the efficacy of different induction regimens in patients with initially unresectable colorectal cancer liver metastases. The results showed that FOLFOXIRI-bevacizumab was the preferred treatment for patients with right-sided primary tumor or RAS/BRAFV600E mutation, while the addition of panitumumab to FOLFOX or FOLFIRI in patients with left-sided and RAS/BRAFV600E wild-type tumor showed no clinical benefit but more toxicity.
Article
Oncology
Leonard B. Saltz, Stephen Clarke, Eduardo Diaz-Rubio, Werner Scheithauer, Arie Figer, Ralph Wong, Sheryl Koski, Mikhail Lichinitser, Tsai-Shen Yang, Fernando Rivera, Felix Couture, Florin Sirzen, Jim Cassidy
Summary: The purpose of this study was to evaluate the efficacy and safety of adding bevacizumab to first-line oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. The results showed that adding bevacizumab significantly improved progression-free survival, but had no significant effect on overall survival and response rate.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Changjing Cai, Qingqing Luo, Yihan Liu, Yinghui Peng, Xiangyang Zhang, Zhaohui Jiang, Ziyang Feng, Yaru Qi, Yan Gao, Yongting Liu, Ping Liu, Yihong Chen, Cao Guo, Hong Shen, Shan Zeng, Ying Han
Summary: This study conducted a comprehensive analysis of treatment regimens for left-sided RAS wild-type metastatic colorectal cancer (mCRC) and found that the double-drug regimen plus cetuximab/panitumumab was more effective and safer than the double-drug and triple-drug regimens with bevacizumab.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Gerald W. Prager, Julien Taieb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Elez, Felipe M. Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Papai, Pierre-Guillaume Poureau, Gabor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik P. Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loick Vidot, Josep Tabernero
Summary: In this study, researchers found that treatment with trifluridine-tipiracil plus bevacizumab could prolong overall survival in patients with metastatic colorectal cancer compared to trifluridine-tipiracil alone.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Arndt Stahler, Dominik P. Modest, Ludwig Fischer von Weikersthal, Florian Kaiser, Thomas Decker, Swantje Held, Ullrich Graeven, Ingo Schwaner, Claudio Denzlinger, Michael Schenk, Annika Kurreck, Kathrin Heinrich, Clemens Giessen-Jung, Jens Neumann, Thomas Kirchner, Andreas Jung, Sebastian Stintzing, Volker Heinemann
Summary: The XELAVIRI trial did not demonstrate non-inferiority overall, but sequential treatment showed non-inferiority in elderly patients and those with RAS mutant tumors.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Kentaro Yamazaki, Satoshi Yuki, Eiji Oki, Fumikazu Sano, Misako Makishima, Kenichi Aoki, Tetsutaro Hamano, Kouji Yamamoto
Summary: In this study, the baseline characteristics and efficacies of intensive and less intensive therapies for metastatic colorectal cancer were compared. Patient age and daily activity levels were found to be important factors in determining treatment intensity.
